A clinical response to EGFR-TKIs in patients with EML4-ALK-positive lung adenocarcinoma has been previously observed in cases that harbour a coexisting EGFR mutation and EML4-ALK translocation (13–15). Here, ALK is linked to lung adenocarcinoma.